News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA) Defends Experimental Med at Diabetes Meeting



10/5/2012 8:19:42 AM

Sanofi (SAN) defended its experimental drug Lyxumia after some scientists questioned the medicine’s novelty at a diabetes conference. Lyxumia isn’t “at all” an imitation of Bristol-Myers Squibb Co. (BMY)’s Byetta, Pierre Chancel, who heads Sanofi Diabetes, said yesterday in Berlin, where he attended the European Association for the Study of Diabetes conference. The drug is “as effective as Byetta with one injection a day, super simple to use and super safe,” he said in an interview. Sanofi needs to show Lyxumia helps patients who suffer from the most common form of diabetes, known as type 2, control the level of sugar in their blood with one injection a day to gain an edge over Byetta, which requires two shots, and other drugs from the same class. At the conference this week, participants questioned whether Lyxumia really requires only one shot.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES